Sodium oxybate
Brand names: Xyrem
Sodium oxybate, the sodium salt of gamma-hydroxybutyrate, is used to treat cataplexy and excessive daytime sleepiness in adults with narcolepsy.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a central nervous system depressant acting at GABA-B and GHB receptors, consolidating night-time sleep architecture which reduces daytime sleepiness and cataplexy.
Prescribing in practice
- It is a potent CNS depressant with a high risk of respiratory depression and abuse, and must never be combined with alcohol, opioids or other sedating agents.
- It carries a substantial sodium load, which is relevant in heart failure, hypertension and renal impairment, and a low-sodium oxybate formulation exists.
- Doses are taken at night in two divided portions, the first at bedtime and the second a few hours later, with the patient remaining in bed.
Monitoring
Monitor for respiratory depression, excessive sedation, mood or behavioural changes, sleep-related breathing disorders and signs of dependence, alongside blood pressure given the sodium content.
Counselling the patient
- Never drink alcohol or take other sedatives with this medicine; doing so can dangerously slow your breathing.
- Prepare both night-time doses in advance, take them while in bed, and do not drive until you know how it affects you.
- Keep it securely stored, as it has potential for misuse and diversion.
Evidence & guidelines
Randomised controlled trials demonstrate reduced cataplexy and daytime sleepiness in narcolepsy, and it is supplied within a controlled distribution framework reflecting MHRA and SPC safety warnings.
Reference: NICE; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS